Valuation: Beacon Pharmaceuticals PLC

Market Cap 25.48B 207M 179M 168M 153M 288M 19.74B 293M 1.98B 773M 9.88B 776M 760M 32.96B P/E 2024
68.2x
P/E 2025 25.8x
Enterprise Value 35.44B 288M 249M 234M 213M 401M 27.46B 408M 2.75B 1.07B 13.75B 1.08B 1.06B 45.85B EV / Sales 2024
4.25x
EV / Sales 2025 2.74x
Free-Float
36.94%
Yield 2024
1.3%
Yield 2025 1.98%
1 day-1.02%
1 week-0.46%
Current month-1.20%
1 month-6.38%
3 months+4.38%
6 months+0.19%
Current year+2.49%
1 week 106.8
Extreme 106.8
109.1
1 month 106.8
Extreme 106.8
116
Current year 96
Extreme 96
117.9
1 year 96
Extreme 96
147.5
3 years 92.4
Extreme 92.4
288.9
5 years 92.4
Extreme 92.4
393
10 years 16
Extreme 16
393
Manager TitleAgeSince
Chief Executive Officer - -
Director of Finance/CFO - -
Chief Administrative Officer - -
Director TitleAgeSince
Chairman 67 -
Director/Board Member 42 -
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
-1.02%-0.46%-2.01%-56.24% 201M
-0.92%+1.43%+83.05%+128.86% 1,078B
+0.47%+1.98%+50.26%+50.75% 632B
+0.83%+2.85%+24.49%+64.82% 443B
-1.09%-2.56%+43.10%+35.13% 356B
-0.80%-2.70%+24.36%+34.82% 289B
-1.27%-2.93%-0.33%+3.90% 245B
+0.40%+3.21%+44.42%+59.17% 226B
+1.35%-1.11%-7.03%-51.28% 204B
+1.67%+5.56%+14.98%+72.68% 171B
Average -0.05%+1.31%+27.53%+34.26% 364.39B
Weighted average by Cap. -0.17%+1.30%+45.44%+65.47%

Financials

2024 2025
Net sales 10.7B 86.87M 75.3M 70.59M 64.36M 121M 8.29B 123M 831M 324M 4.15B 326M 319M 13.84B 12.54B 102M 88.25M 82.73M 75.44M 142M 9.72B 144M 974M 380M 4.86B 382M 374M 16.23B
Net income 521M 4.23M 3.67M 3.44M 3.13M 5.9M 404M 5.99M 40.46M 15.8M 202M 15.88M 15.53M 674M 947M 7.68M 6.66M 6.24M 5.69M 10.71M 733M 10.88M 73.51M 28.7M 367M 28.85M 28.22M 1.22B
Net Debt 10B 81.15M 70.34M 65.94M 60.12M 113M 7.74B 115M 776M 303M 3.88B 305M 298M 12.93B 9.96B 80.88M 70.1M 65.72M 59.92M 113M 7.72B 115M 774M 302M 3.86B 304M 297M 12.89B
Logo Beacon Pharmaceuticals PLC
Beacon Pharmaceuticals PLC is a Bangladesh-based pharmaceutical company. The Company is engaged in the manufacturing and marketing of pharmaceutical finished formulation products and lifesaving Intravenous (I.V) fluids, active pharmaceuticals ingredients, biotech products, and genetic engineering products which it sells in the local markets as well as the international markets. The Company also provides contract and toll manufacturing services. Its products are focused on various drugs, such as anticancer, cardiovascular, gastrointestinal, antibiotics, anti-coagulants, protein supplements, muscle relaxant, antihistamine, analgesics, and non-steroidal anti-inflammatory drugs (NSAIDS), among others. The Company's product categories include general, oncology, anti-viral, and biotech. Its products include Tagrix 80, Afanix 40, Ibrutix, Lenvanix 4, Palbonix, Crizonix, Sunitix, Wedica, Tafecta, Hernix, Obetix, Ribotix, among others.
Employees
4,771
Date Price Change Volume
13/08/26 BDT 107.20 -1.02% 115,981
12/08/26 BDT 108.30 +0.19% 107,817
11/08/26 BDT 108.10 +0.93% 82,296
10/08/26 BDT 107.10 +0.09% 96,141
09/08/26 BDT 107.00 -0.65% 149,504
  1. Stock Market
  2. Stocks
  3. BEACONPHAR Stock